References
- Mossialos E, Kanavanos P, Abel-Smith B. Will managed care work in Europe? Pharmacoeconomics 1997; 11: 297–305.
- Grimshaw JM, Russell IT. Achieving health gain through clinical guidelines. 1. Developing scientifically valid guidelines. Quality Health Care 1993; 2: 243–8.
- Bochner F, Martin ED, Burgess NG, Somogyi AA, Misan GMH on behalf of the Drug Committee of the Royal Adelaide Hospital. Drug rationing in a teaching hospital: a method to assign priorities. Br Med J 1994; 308: 901–5.
- Lipsy RJ. Institiutional formularies. The relevance of pharmacoeconomic analysis to formulary decisions. Pharmacoeconomics 1992; 1: 265–81.
- Ciproxin Summary of Product Characteristics, Bayer 1998.
- Raxar Summary of Product Characteristics, Allen & Hanburys 1997.
- Haria M, Lamb HM. Trovafloxacin. Drugs 1997; 54: 435–45.
- Levofloxacin Tablets Summary of Product Characteristics, Hoechst Marion Roussel 1997.
- Ball P, Fernald A, Tillotson G. Therapeutic advances of new fluoroquinolones. Exp Opin Invest Drugs 1998; 7: 1–23.
- Andrews JM, Honeybourne D, Jevons G, Brenwald NP, Cunningham B, Wise R. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 40: 573–7.
- Ernst ME, Ernst EJ, Klepser ME. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? Am J Health-Syst Pharm 1997; 54: 2569–84.
- Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalised patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastin. Antimicrob Agents Chemother 1995; 38: 547–57.
- Caldwell J, Singh S, Johnson R. Pattern of subsequent infection and antibiotic use following initial treatment with ciprofloxacin versus imipenem for nosocomial pneumonia. 34th Interscience Congress of Antimicrobial Agents and Chemotherapy, Orlando, USA, 1994; Abstract M49.
- Rifenberg RP, Paladino JA, Bhavnani SM, Haese DD, Schentag JJ. Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health System Pharm 1999; 56 (21): 227-33.
- Nathwani D, Tillotson G, Davey P. Sequential antimicrobial therapy – the role of quinolones. J Antimicrob Chemother 1997; 39: 441–6.